LIGANDAL
Ligandal is solving the delivery problem of complex therapies and enabling precision genetic medicine. By creating cell- and tissue-specific delivery technologies of gene therapies and gene editors such as CRISPR and mRNA, using synthetic peptides as targeting modalities, we develop and deliver therapeutic solutions for creating the next generation of targeted therapies.
By combining machine learning models, peptide chemistry, nanotechnology, and biological studies with our proven AI engine, we allow for the rapid discovery, design and development of novel peptide therapeutics and delivery systems geared for the 21st century of medicine.
We are back by 10 years of foundational R&D efforts and 58 pending global patents. Ligandal is the owner of one of the largest AI+peptide patent portfolios in the world. We have locked up the discovery, development, and manufacturing of these unique targeted drug delivery peptide nanomaterials.
li·gand
noun
BIOCHEMISTRY
a molecule that binds to another (usually larger) molecule.
Imagine a world where we can reprogram biology precisely and predictively for the betterment of humankind and the planet. We believe in that world and want to see the ultimate good for global health and longevity arise from these capabilities and technologies, their implementation, and their distribution.
Ligandal is a leader in the interface of computational biology, machine learning, and AI with nanomaterials and delivery technologies for developing the next generation of precision medicine. Our platform of peptide-based nanomaterials enables applications for gene therapy, gene editing, regenerative medicine, immunotherapy, and next-generation antidote-vaccine technologies to benefit our civilization.
Ligandal is akin to the invention of GPS and shipping routes for molecular delivery technologies. We make technologies such as mRNA and CRISPR, which are foundational to gene therapy and editing, able to reach their targets. Effectively, this expands the addressable "zip codes" of biology and therapeutics.
By combining machine learning models, peptide chemistry, nanotechnology, and biological studies with our proven AI engine, we allow for the rapid discovery, design and development of novel peptide therapeutics and delivery systems geared for the 21st century of medicine.
We are back by 10 years of foundational R&D efforts and 58 pending global patents. Ligandal is the owner of one of the largest AI+peptide patent portfolios in the world. We have locked up the discovery, development, and manufacturing of these unique targeted drug delivery peptide nanomaterials.
li·gand
noun
BIOCHEMISTRY
a molecule that binds to another (usually larger) molecule.
Imagine a world where we can reprogram biology precisely and predictively for the betterment of humankind and the planet. We believe in that world and want to see the ultimate good for global health and longevity arise from these capabilities and technologies, their implementation, and their distribution.
Ligandal is a leader in the interface of computational biology, machine learning, and AI with nanomaterials and delivery technologies for developing the next generation of precision medicine. Our platform of peptide-based nanomaterials enables applications for gene therapy, gene editing, regenerative medicine, immunotherapy, and next-generation antidote-vaccine technologies to benefit our civilization.
Ligandal is akin to the invention of GPS and shipping routes for molecular delivery technologies. We make technologies such as mRNA and CRISPR, which are foundational to gene therapy and editing, able to reach their targets. Effectively, this expands the addressable "zip codes" of biology and therapeutics.
